<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999700</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT NUMBER 2009-013402-14</org_study_id>
    <nct_id>NCT00999700</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin</brief_title>
  <acronym>INTERCEPTOR</acronym>
  <official_title>Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III trial of induction chemotherapy followed by definitive radiotherapy plus
      Cetuximab versus chemoradiation in unresectable, locally advanced, squamous cell carcinoma of
      the head and neck (HNC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to determine whether Cetuximab and radiation preceded by an
      induction chemotherapy, may be superior to an established chemoradiation program for HNC
      (RTOG regimen, Adelstein DJ J.Clin.Oncol. 2003;21:92-98).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicities in the two arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel - cisplatin - 5-fluorouracil</intervention_name>
    <description>docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.</description>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.</description>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  Histologically or cytologically confirmed diagnosis of HNSCC

          -  Stage III/IV, not suitable for surgery (definitive cure rate improbable, technically
             unresectable or medical contraindication for surgery)

          -  At least one uni-dimensional measurable lesion either by CT scan or MRI

          -  Signed written informed consents prior to beginning protocol

        Specific procedures:

          -  Tumor tissue available for immunohistochemical staining of EGFR expression and HPV

          -  Life expectancy of &gt; 3 months at study entry

          -  ECOG Performance Status of &lt;2 at study entry.

          -  Effective contraception if risk of conception exists.

          -  Neutrophils &gt; 2.0/mm³, platelet count &gt; 100,000/mm³, and hemoglobin &gt; 10 g/dl

          -  Normal liver function

          -  Serum creatinine &gt; 1.25 x ULN and/or creatinine clearance &gt; 60 ml/min

        Exclusion Criteria:

          -  Prior systemic chemotherapy and/or radiotherapy

          -  Known peripheral neuropathy &gt; grade 2 NCI-CTC version 3.0

          -  Known chronic heart failure

          -  Prior surgery, excluding prior diagnostic biopsy

          -  Known drug abuse

          -  Active uncontrolled infection

          -  Other concomitant anticancer therapy

          -  Distant metastasis

          -  Concurrent chronic systemic immune therapy, chemotherapy for disease other than
             cancer, or hormone therapy not indicated in the study protocol

          -  Clinically relevant coronary artery disease or history of a myocardial infarction
             within the last 12 months before study entry

          -  Medical or psychological condition that would not permit the patient to complete the
             trial or sign informed consent

          -  Nasopharyngeal carcinoma WHO type II or III

          -  Known allergic reaction against any of the components of the treatment

          -  Pregnancy (absence confirmed by beta-HCG test) or lactation period

          -  Any prior or on-going investigational medication

          -  Previous or current malignancy except basal cell carcinoma of the skin or pre-invasive
             carcinoma of the cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARCO MERLANO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASCO, ESMO, AIOM, G.O.N.O.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Civile Ss. Antonio E Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Della Valle D' Aosta</name>
      <address>
        <city>Aosta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl 8 - Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.O. S. Croce E Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs - Aou S. Martino - Oncology</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs - Aou San Martino - Radiotherapy</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl 3 Genovese</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Villa Scassi - Asl3</name>
      <address>
        <city>Italy</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giacomo</name>
      <address>
        <city>Novi Ligure (al)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Di Fano</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob)</name>
      <address>
        <city>Rionero in Vulture (pz)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Filippo Neri</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Savona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Torino (to)</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Giovanni Battista-Molinette Di Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.reteoncologica.it/</url>
    <description>click on &quot;trials&quot; for more informations</description>
  </link>
  <results_reference>
    <citation>- J.P. Pignon et al. Lancet 2000</citation>
  </results_reference>
  <results_reference>
    <citation>- A. Forastiere et al., New Engl J Med 2001</citation>
  </results_reference>
  <results_reference>
    <citation>Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8.</citation>
    <PMID>12506176</PMID>
  </results_reference>
  <results_reference>
    <citation>Henke-Gendo C, Schulz TF, Hoeper MM. HHV-8 in pulmonary hypertension. N Engl J Med. 2004 Jan 8;350(2):194-5; author reply 194-5.</citation>
    <PMID>14711924</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.</citation>
    <PMID>16467544</PMID>
  </results_reference>
  <results_reference>
    <citation>Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist. 2006 Feb;11(2):146-51. Review.</citation>
    <PMID>16476835</PMID>
  </results_reference>
  <results_reference>
    <citation>- Posner M et al, New Engl J Med 2007</citation>
  </results_reference>
  <results_reference>
    <citation>- Vermorken J et al, New Engl J Med 2007</citation>
  </results_reference>
  <results_reference>
    <citation>Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M. Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.</citation>
    <PMID>19499245</PMID>
  </results_reference>
  <results_reference>
    <citation>- Merlano M et al, Cancer Treat Rev 2003</citation>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gruppo Oncologico del Nord-Ovest</investigator_affiliation>
    <investigator_full_name>MARCO MERLANO</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Locally advanced HNSCC</keyword>
  <keyword>Chemo-radiation</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Stage III/IV</keyword>
  <keyword>Unresectable disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

